Soares Adriana Watts, Maia Maria, Santo João Espirito, Costa Ana Palricas, Pereira Artur, Catarino Cristina
Internal Medicine Department, Hospital Beatriz Ângelo, Loures, Portugal.
Immunohemotherapy Department, Hospital Santa Maria, Lisbon, Portugal.
Eur J Case Rep Intern Med. 2020 Jan 28;7(2):001424. doi: 10.12890/2020_001424. eCollection 2020.
The authors present the case of a 27-year-old patient who suffered from spontaneous bleeding during infancy and from a severe and central venous thrombosis in adult years. The patient underwent a thorough laboratory work-up on both occasions and was diagnosed with hypofibrinogenaemia as well as protein S deficiency, 2 diseases that contrast in their intrinsic bleeding/thrombotic risk. The patient's high-risk pregnancy was carried out up to a successful full-term eutocic delivery which required fibrinogen concentrate to reduce life-threatening bleeding. The patient's child was also diagnosed with hypofibrinogenaemia, later on confirmed with the pathogenic mutation Fibrinogen Marseilles II. This case was used to conduct a literature review of congenital fibrinogen disorders, rare entities that require more awareness for early diagnosis and accurate management.
Fibrinogen disorders are uncommon causes of either bleeding or thrombotic events and may be acquired or inherited in a recessive or dominant autosomal manner.Congenital fibrinogen deficiencies are rare but should be investigated when undergoing diagnostic work-up for thrombotic or haemorrhagic events in adult years.Determination of molecular defects is important for confirmation and to elaborate a treatment strategy according to the inherent risk for either thrombotic or haemorrhagic events.
作者介绍了一名27岁患者的病例,该患者在婴儿期出现自发性出血,成年后发生严重的中心静脉血栓形成。患者在这两种情况下都接受了全面的实验室检查,被诊断为低纤维蛋白原血症以及蛋白S缺乏症,这两种疾病在其内在出血/血栓形成风险方面形成对比。患者的高危妊娠顺利进行至足月顺产,分娩时需要使用纤维蛋白原浓缩物来减少危及生命的出血。患者的孩子也被诊断为低纤维蛋白原血症,后来通过致病突变纤维蛋白原马赛II型得到确诊。该病例用于对先天性纤维蛋白原疾病进行文献综述,这些罕见疾病需要更多关注以便早期诊断和准确管理。
纤维蛋白原疾病是出血或血栓形成事件的罕见原因,可能以隐性或显性常染色体方式获得或遗传。先天性纤维蛋白原缺乏症很少见,但在成年后因血栓形成或出血事件进行诊断检查时应进行调查。确定分子缺陷对于确诊以及根据血栓形成或出血事件的固有风险制定治疗策略很重要。